Skip to main content
Biosimilars
Biosimilars Year in Review Introduction
Read More
Biosimilars
Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab
Read More
Biosimilars
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
Read More
Breast Cancer, CDK4/6 Inhibitors
Comparison of Healthcare Resource Utilization and Costs in Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Read More
Breast Cancer, CDK4/6 Inhibitors
Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings
Read More
Breast Cancer
Assessment of Characteristics, Utilization Patterns, and Outcomes in the Real-World Setting of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with Abemaciclib
Read More
Breast Cancer
Capecitabine or Endocrine Therapy as Maintenance Therapy for Hormone Receptor–Positive, HER2-Negative Breast Cancer
Read More
Breast Cancer
Real-World Data of Palbociclib and Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Impact of the COVID-19 Pandemic in the United States on First-Line Treatment Trends in Metastatic Breast Cancer
Read More
Breast Cancer
Updated Results from the Phase 3b CompLEEment-1 Study of Ribociclib plus Letrozole in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Page 106 of 200
Results 1051 - 1060 of 1993